Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation (The CIC3 Study)

Next Previous
Trial Profile

A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation (The CIC3 Study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plecanatide (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Acronyms CIC3
  • Sponsors Bausch Health Companies; Synergy Pharmaceuticals Inc

    • Most Recent Events

    • 26 Oct 2022 Results of post hoc pooled analysis from NCT01982240; NCT02122471, NCT02387359, NCT02493452; evaluating the potential impact of age on plecanatide efficacy in Chronic Idiopathic Constipation and IBS-C, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
    • 24 Jan 2022 Results of pooled analysis from (NCT02122471 and NCT01982240) assessing efficacy and safety along with concomitant acid suppression therapy's effect published in the Clinical Therapeutics
    • 27 Oct 2021 Results of a post-hoc analysis from two studies (NCT01982240, NCT02122471) presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top